menu
Insights, News, & Events arrow_right News arrow_right

THERMO FISHER SCIENTIFIC TO ACQUIRE PATHEON, A LEADING CONTRACT

15 May 2017 Articles

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. 

Morrow Sodali is serving as the proxy solicitor for Patheon N.V.

Media enquiries

To contact our global experts for comments please get in touch below.

Contact us chevron_right

Contact us

close

Sign up with your email